ERBB2 and breast cancer: After PSM, as shown in Figures 5C,D, both OS and BCSS benefits are found between the married and unmarried groups for patients with HR+/HER2– breast cancer (OS: HR = 1.439, 95% CI: 1.155–1.794, p = 0.0013; BCSS: HR = 1.547, 95% CI: 1.157–2.069, p = 0.0035), while, there were no differences of OS or BCSS prognosis between married and unmarried patients in other three subgroups.